Live Earnings Conference Call: Recursion Pharmaceuticals will host a live Q2 2025 earnings call on August 5, 2025 at 8:00AM ET. Follow this link to get details and listen to Recursion Pharmaceuticals' Q2 2025 earnings call when it goes live. Get details. NASDAQ:RXRX Recursion Pharmaceuticals Q3 2024 Earnings Report $5.80 +0.12 (+2.11%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$5.78 -0.02 (-0.40%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Recursion Pharmaceuticals EPS ResultsActual EPS-$0.34Consensus EPS -$0.33Beat/MissMissed by -$0.01One Year Ago EPS-$0.43Recursion Pharmaceuticals Revenue ResultsActual Revenue$26.08 millionExpected Revenue$12.62 millionBeat/MissBeat by +$13.46 millionYoY Revenue Growth+147.60%Recursion Pharmaceuticals Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call DateWednesday, November 6, 2024Conference Call Time4:00PM ETUpcoming EarningsRecursion Pharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Recursion Pharmaceuticals Earnings Headlines2 Beaten-Down Stocks With Incredible Upside PotentialAugust 3 at 12:32 PM | fool.comRecursion Pharmaceuticals (RXRX) Price Surges 9% Over Past MonthAugust 2 at 6:17 PM | finance.yahoo.comCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? Depending on when you watch this new training, crypto income could be hitting your account as early as tonight! | Awesomely, LLC (Ad)Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5thJuly 29, 2025 | globenewswire.comWhy Recursion Pharmaceuticals Stock Got Mashed on MondayJuly 28, 2025 | fool.comTempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better?July 28, 2025 | 247wallst.comSee More Recursion Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Recursion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Recursion Pharmaceuticals and other key companies, straight to your email. Email Address About Recursion PharmaceuticalsRecursion Pharmaceuticals (NASDAQ:RXRX) operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.View Recursion Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Why Robinhood Just Added Upside Potential After a Q2 Earnings DipMicrosoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead? Upcoming Earnings Fortinet (8/6/2025)Airbnb (8/6/2025)DoorDash (8/6/2025)AppLovin (8/6/2025)Energy Transfer (8/6/2025)Sony (8/6/2025)Manulife Financial (8/6/2025)Novo Nordisk A/S (8/6/2025)Realty Income (8/6/2025)Brookfield Asset Management (8/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
